Table 1.
Characteristics of studies included in the systematic review by country
| Author, year [reference] | Region | Age range, years | Antibody response (type) | Study design (n) a | Plasmodium vivax outcome b |
|---|---|---|---|---|---|
| Brazil | |||||
| Fernandez-Becerra, 2010 [22]c | Rio Machado | DNS | PvMSP-1NT, PvMSP-119 (IgG) | CS (87) | Pv infection (LM or PCR), symptomatic Pv |
| Kano, 2012 [23] | Presidente Figueiredo, Amazonas | 9 to 44 | PvDBPII-IV, PvMSP-119 (IgG) | CS (432) | Pv infection (LM or PCR), symptomatic Pv |
| Lima-Junior, 2008 [24]d | Rondonia | 10 to 85 | PvMSP-9RIRII, PvMSP-9RII, PvMSP-9NT (IgG) | CS (282) | Pv infection |
| Lima-Junior, 2011 [25] | Rondonia | 10 to 81 | PvMSP-3αFL, PvMSP-3αNT, PvMSP-3αRI, PvMSP-3αRII, PvMSP-3αCT (IgG) | CS (282) | Pv infection |
| Lima-Junior, 2012 [26] | Rondonia | 11 to 89 | PvMSP-119 (IgG) | CS (277) | Pv infection |
| Nogueira, 2006 [27] | Portuchuelo, Rondonia | DNS | PvMSP-1NT, PvMSP-119 (IgG) | Cohort (173) | Pv infection |
| Oliveira-Ferreira, 2004 [28] | Candeias do Jamari, Rondonia | 12 to 74 | PvCSP (VK210, VK247, P. vivax-like) (IgG) | CS (61) | Pv infection |
| Souza-Silva, 2010 [29] | Acre | 5 to 90 | PvDBPII-IV (IgG) | Cohort (CS)e (366) | Pv infection, Pv infection (LM or PCR) |
| Tran, 2005 [30]f | Colina and Ribeirinha, Rondonia | 11 to 75 | PvRBP1 (IgG) | CS (87) | Pv infection |
| Versiani, 2013 [31] | Rio Pardo | DNS | PvMSP-1NT (IgG, IgG1, IgG2, IgG3, IgG4) | Cohort (CS)e (308) | Pv infection, symptomatic Pv |
| Indonesia | |||||
| Ak, 1998 [32] | Robek | 0 to 73 | PvMSP-119 (IgG + IgM) | CS (169) | Pv infection |
| Woodberry, 2008 [33] | Timika, Papua | 3 to 60 | PvMSP-5 (IgG, IgM, IgG1, IgG2, IgG3, IgG4) | CC (340) | Symptomatic Pv |
| Papua New Guinea | |||||
| Cole-Tobian, 2009 [34] | Madang | 5 to 14 | PvDBPII (AH, O, P, Sal 1), PvMSP-119 (IgG) | Cohortg (206) | Pv infection, Pv infection (LDR-FMA), Pv infection >150 parasites/μl |
| Fernandez-Becerra, 2010 [22] | Madang | 0.25 to 3 | PvMSP-1NT, PvMSP-119 (IgG) | CS (100) | Pv infection (LM or PCR), symptomatic Pv |
| King, 2008 [35] | Madang | 5 to 14 | PvDBPII binding inhibitory antibodies | Cohort (206)h | Pv infection |
| Stanisic, 2013 [36] | East Sepik | 0.9 to 3.1 | PvMSP-3αNT, PvMSP-3αRI, PvMSP-3αRII, PvMSP-3αCT, PvMSP-9NT, PvMSP-9RIRII (IgG) | Cohort (CS)e (183) | Pv infection (LDR-FMA), symptomatic Pv |
| Thailand | |||||
| Fowkes, 2012 [37] | Mae Sot, Tak | 15 to 42i | PvAMA1-ecto (IgG) | Nested CC (467) | Pv infection |
| Wongsrichanalai, 1991 [38] | Chanthaburi | DNS | PvCSP (VK210) (IgG) | CC (126) | Pv infection |
| Turkey | |||||
| Yildiz Zeyrek, 2011 [39] | Sanliurfa | 0 to 77 | PvMSP-119, PvAMA1-ecto, PvSERA4, PvCSP (VK210 and VK247 chimera) (IgG, IgM, IgG1, IgG2, IgG3, IgG4) | CS (195) | Pv infection |
CC, case–control; CS, cross-sectional; DNS, did not state; LDR-FMA, ligase detection reaction–fluorescent microsphere assay; LM, light microscopy; PV, Plasmodium vivax.
aSample size refers to number of participants for whom serology was determined.
b P. vivax infection was determined by light microscopy unless otherwise stated.
cFernandez-Becerra, 2010 [22] reported studies performed in two countries and features twice in Table 1.
dThe studies described by Lima-Junior in 2008 and 2012 [24,26] were conducted in the same area, but the participants were different.
eCohort study with cross-sectional data also included.
fTran, 2005 [30] included data from two different study sites in Brazil.
gTreatment to re-infection study.
hKing, 2008 [35] reported estimates from the same treatment to re-infection study as that described by Cole-Tobian, 2009 [34].
iThis study comprised pregnant women.